Verve Therapeutics Funding: $216M Raised, Series B (2021)
Verve Therapeutics is based in Burlington, MA. It has raised $216M in total funding. Latest round: Series B.
Verve Therapeutics funding overview
Verve Therapeutics is based in Burlington, MA. Verve Therapeutics has raised $216M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in January 2021. The round record for Verve Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include ELI Casdin, Wellington Management, Brainchild, F Prime Capital, GV, OAK HC/FT and 11 others. 17 distinct backers are named across the disclosed rounds.
Verve Therapeutics at a glance
Total raised
$216M
Latest round
Series B
Latest round date
January 2021
Headquarters
Burlington, MA
Notable investors
ELI Casdin, Wellington Management, Brainchild, F Prime Capital, GV, OAK HC/FT, Nicolas Berggruen, Biomatics Capital
Frequently asked about Verve Therapeutics funding
How much has Verve Therapeutics raised?
Verve Therapeutics has raised $216M in total disclosed funding across the rounds on record.
Who has invested in Verve Therapeutics?
ELI Casdin, Wellington Management, Brainchild, F Prime Capital, GV, OAK HC/FT are named among the investors backing Verve Therapeutics.
What was the latest Verve Therapeutics funding round?
The most recent disclosed round is a Series B, announced in January 2021.
Where is Verve Therapeutics based?
Verve Therapeutics is based in Burlington, MA.
When did Verve Therapeutics last raise?
The last disclosed Verve Therapeutics round closed in January 2021 at Series B.
Round data for Verve Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Burlington and backer lists below.
